Anticancer Activity of PLK1 Inhibitor BI-2536 and β-Glucan in HT-29 and AGS Cancer Cell Lines
Preprint
- 31 July 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-glucan, a natural immunomodulator, has also demonstrated anticancer potential. Objective: This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines. Methods: Cell viability was assessed by XTT assay. Apoptosis and cell cycle profiles were evaluated by flow cytometry. The combination index (CI) was calculated using the Chou–Talalay method via CompuSyn software. Results: BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-glucan showed moderate cytotoxicity and enhanced BI-2536’s effects in combination. Synergistic antiproliferative activity was observed at lower drug concentrations (CI < 1), with the combination inducing greater apoptosis and G2/M arrest than monotherapy. Mechanistically, this synergy may involve dual restoration of FOXO3 activity via PLK1 inhibition and PI3K/AKT/mTOR suppression. Conclusion: BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers. Further in vivo studies are warranted.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- A novel strategy to enhance inhibition of Hela cervical cancer by combining Lentinus β-glucan and autophagic flux blockageInternational Journal of Biological Macromolecules, 2024
- Tannic acid protects neuroblastoma cells against hydrogen peroxide – triggered oxidative stress by suppressing oxidative stress and apoptosisBrain Research, 2024
- Mechanism of anticancer effect of ETP-45658, a PI3K/AKT/mTOR pathway inhibitor on HT-29 CellsMedical Oncology, 2023
- Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistanceGastric Cancer, 2021
- The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistanceSeminars in Cancer Biology, 2018
- Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinomaCancer Letters, 2016
- Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cellsCancer Letters, 2015
- Treatment of Metastatic Colorectal CancerSeminars in Oncology, 2011
- Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progressionNature Cell Biology, 2008
- Polo-like kinases (Plks) and cancerOncogene, 2005